Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CureTech Ltd
ClinicalTrials.gov Identifier:
NCT01435369
First received: September 8, 2011
Last updated: September 30, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2013
  Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)